Spend :01 of your time each Monday morning as Twelve:01 delivers timely tools, trends, strategies, and/or compliance insights for the CME/CE enterprise.
A recent McKinsey & Company article explores how digital therapeutics (DTx) are poised to revolutionize chronic-disease management by addressing gaps in monitoring, medication adherence, and behavioral change. The article highlights compelling data, including a reported 45% reduction in major adverse cardiovascular events and a 50% drop in 30-day readmissions for patients using digital-health interventions. Strong DTx solutions typically contain eight key design elements, such as connected-device feedback loops, gamified behavior change, personalized coaching, and advanced analytics. DTx showcases clinical innovation, as well as a major growth frontier, offering improved outcomes for patients and new value-chain opportunities for payers, providers, and life-sciences companies.
Oscar Health and Elektra Health’s HelloMeno – the first menopause-focused health plan on the ACA marketplace – marks a pivotal step toward equitable, affordable, and personalized care for women 45 and older. With $0 cost visits for primary care, gynecology, and behavioral health, plus access to menopause-trained clinicians and preventive care rewards, the plan delivers comprehensive midlife support across 11 states. Its debut comes amid rising recognition that women’s health is not just a clinical priority but a major economic opportunity: as Forbes (Feb 2025) notes, investing in women’s health could unlock up to $1 trillion in global economic growth by 2040. Opportunities may exist for CME/CE providers, to deliver evidence-based, life-stage focused education to meet this expanding frontier.
As AI rapidly integrates into healthcare, strong governance is the backbone of responsible innovation. The Institute for Healthcare Improvement emphasizes that effective governance, spanning use case selection to post-deployment monitoring, is essential to both patient safety and trust. A robust framework should combine multidisciplinary oversight, scalable accountability, and clear policies for all AI tools, including non-clinical applications. Health systems must lead the way in defining what “safe and effective AI” means for patient care.
